(secondQuint)An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II).

 This was a Phase IV, open-label, non-randomized, multi-center study conducted in community based practices, physicians networks, or academic institutions in the US.

 This study included anemic (Hb = 13 g/dL were converted to a maintenance dose of PROCRIT (Epoetin alfa) sc Q2W.

.

 An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)@highlight

The objective of this study was to treat anemic (Hemoglobin (Hb) 13 g/dL and then to assess if the target Hb level and improvements in Quality of Life (QOL) could be maintained with every other week (Q2W) PROCRIT (Epoetin alfa) dosing.

